A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
Authors
Keywords
-
Journal
ESMO Open
Volume 6, Issue 5, Pages 100272
Publisher
Elsevier BV
Online
2021-09-01
DOI
10.1016/j.esmoop.2021.100272
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Commentary: SARS-CoV-2 vaccines and cancer patients
- (2021) C. Corti et al. ANNALS OF ONCOLOGY
- SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: recommendations from the French society for Immuno-Therapy of Cancer (FITC)
- (2021) Marie-Léa Gauci et al. EUROPEAN JOURNAL OF CANCER
- Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2
- (2021) Saman Saadat et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay
- (2021) Irene Cassaniti et al. CLINICAL MICROBIOLOGY AND INFECTION
- Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose
- (2021) Hubert Blain et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
- (2021) Barliz Waissengrin et al. LANCET ONCOLOGY
- Seroconversion rates following COVID-19 vaccination among patients with cancer
- (2021) Astha Thakkar et al. CANCER CELL
- High levels of anti–SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine
- (2021) Dominic Fong et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
- (2021) Amir Massarweh et al. JAMA Oncology
- Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020
- (2020) Elena Percivalle et al. Eurosurveillance
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
- (2020) Marina Chiara Garassino et al. LANCET ONCOLOGY
- LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study
- (2020) A. Marra et al. ANNALS OF ONCOLOGY
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
- (2013) Lorry G. Rubin et al. CLINICAL INFECTIOUS DISEASES
- Immune Senescence and Vaccination in the Elderly
- (2013) Pierre Lang et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Reversing T cell immunosenescence: why, who, and how
- (2012) Pierre Olivier Lang et al. AGE
- Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study
- (2011) F. Tang et al. JOURNAL OF IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started